| Methods |
RCT. Placebo controlled, crossover design.
Blinding not stated.
Masking of assessors not stated.
Single centre. |
| Participants |
10 patients.
Inclusion criteria: Urgency and urge incontinence.
Exclusion criteria: Inflammatory bladder changes, bladder tumours, leucoplasia of bladder or trigone, other urological and gynaecological pathology or inflammation, outflow obstruction, unstable urethra, other use of anticholinergics or spasmolytics. |
| Interventions |
Treatment 1: oxybutynin 5mg tid (n=10)
Treatment 2: propiverine 15mg tid (n=10)
Treatment 3: placebo
3 x 3 week treatment period, no washout. |
| Outcomes |
VAS for effects and side effects.
Frequency of micturition.
Urodynamic parameters.
Residuals.
Laboratory tests. |
| Notes |
Translated from German.
No dropouts.
No follow up.
Data not in useable form for this review. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
